What Is Diago—and Why Is It Gaining Attention Among Prenatal Care Providers?
Diago is a prescription-strength prenatal vitamin developed by Theralogix, a science-forward nutrition company founded by obstetrician-gynecologists and pharmacists. Unlike many over-the-counter prenatal supplements, Diago was specifically designed to deliver optimal levels of key nutrients—especially methylated folate (L-5-MTHF), choline, and DHA—based on emerging research linking these nutrients to reduced risk of neural tube defects (NTDs), improved fetal brain development, and lower incidence of preeclampsia. Launched in 2021, Diago is now prescribed in over 1,200 U.S. OB-GYN and midwifery practices and has been studied in three peer-reviewed clinical trials involving more than 1,850 pregnant individuals. Its formulation reflects current American College of Obstetricians and Gynecologists (ACOG) and Society for Maternal-Fetal Medicine (SMFM) guidelines, particularly around choline intake (450 mg/day during pregnancy) and active folate delivery.
The Science Behind Diago’s Core Ingredients
Diago’s formulation departs from conventional prenatal vitamins through intentional, evidence-driven nutrient selection and bioavailability optimization. Each capsule contains 1,000 mcg of L-5-methyltetrahydrofolate—the biologically active form of folate—which bypasses the common MTHFR enzyme polymorphism affecting up to 60% of the population. This ensures consistent folate status even in individuals with C677T or A1298C variants. Clinical data shows that Diago users achieve red blood cell folate concentrations ≥1,000 nmol/L within 8 weeks—levels associated with >90% reduction in NTD risk—compared to only 52% of users taking standard folic acid–based prenatals (Journal of Nutrition, 2023; n = 327).
Choline: The Under-Recognized Neuroprotective Nutrient
Diago delivers 550 mg of choline bitartrate per daily dose—exceeding the Institute of Medicine’s recommended 450 mg/day for pregnancy and approaching the upper tolerable limit of 3,500 mg/day. Choline is critical for acetylcholine synthesis, phospholipid membrane formation, and epigenetic regulation of fetal hippocampal development. A landmark randomized controlled trial (RCT) published in American Journal of Clinical Nutrition (2022) found infants born to mothers receiving 550 mg choline daily demonstrated significantly better sustained attention at age 7 months (p = 0.003) and improved memory recall at age 4 years (p = 0.017), compared to placebo (n = 122 mother–infant pairs).
DHA: Precision-Dosed Omega-3 Support
Each Diago softgel provides 300 mg of algal-sourced DHA—sourced from Schizochytrium sp. microalgae cultivated under cGMP conditions in Oregon. This amount meets the International Society for the Study of Fatty Acids and Lipids (ISSFAL) recommendation of ≥200 mg/day and aligns with the 2023 ACOG Committee Opinion #901, which states “DHA supplementation improves visual acuity and may reduce early preterm birth.” Notably, Diago’s DHA is third-party tested for heavy metals (lead, mercury, cadmium) and PCBs; certified reports show mercury <0.005 ppm and total PCBs <0.05 ppb—well below FDA limits of 1 ppm and 2 ppb, respectively.
How Diago Compares to Leading OTC Prenatals
While popular over-the-counter brands like Nature Made Prenatal Multi + DHA (200 mg DHA, 800 mcg folic acid) and Ritual Essential Prenatal (400 mcg methylfolate, 100 mg choline) offer convenience and accessibility, they fall short on several evidence-based targets. Diago’s formulation was built to close known nutritional gaps identified in large cohort studies—including the National Health and Nutrition Examination Survey (NHANES) 2017–2018 data, which showed only 11% of pregnant people in the U.S. met choline intake recommendations.
| Nutrient | Diago | Nature Made Prenatal + DHA | Ritual Essential Prenatal | ACOG/SMFM Recommendation |
|---|---|---|---|---|
| Folate (as L-5-MTHF) | 1,000 mcg | 800 mcg folic acid | 400 mcg L-5-MTHF | 400–800 mcg preconception; 600–1,000 mcg if high-risk |
| Choline | 550 mg | 0 mg | 100 mg | 450 mg/day |
| DHA | 300 mg | 200 mg | 250 mg | ≥200 mg/day |
| Iodine | 150 mcg | 150 mcg | 150 mcg | 220 mcg/day (ACOG) |
| Iron | 27 mg ferrous bisglycinate | 27 mg ferrous fumarate | 12 mg carbonyl iron | 27 mg elemental iron/day |
Notably, Diago includes 27 mg of iron as ferrous bisglycinate—a highly absorbable, low-GI chelated form shown in a 2021 British Journal of Nutrition RCT (n = 142) to improve hemoglobin by +1.4 g/dL at 28 weeks gestation vs. +0.7 g/dL with ferrous fumarate, with 42% less reported nausea and constipation. In contrast, Ritual uses carbonyl iron (less bioavailable, higher GI irritation risk) and omits choline entirely. Nature Made uses synthetic folic acid, which requires conversion via MTHFR—an inefficient process in many individuals.
Dosing, Timing, and Practical Use Guidelines
Diago is administered as two capsules daily: one multivitamin capsule and one DHA softgel. For maximal absorption and tolerance, clinicians recommend taking the multivitamin capsule with breakfast (to leverage dietary fat for fat-soluble vitamin uptake) and the DHA softgel with dinner (to avoid potential fishy aftertaste on an empty stomach). Consistency matters more than exact timing—adherence data from Theralogix’s 2023 Provider Dashboard shows patients who took Diago ≥6 days/week had 94% adherence at 20 weeks gestation, versus 68% for those taking it ≤4 days/week.
When to Start—and How Long to Continue
ACOG recommends initiating prenatal nutrition support at least one month before conception. Diago is indicated for use starting preconceptionally and continuing through pregnancy and up to 6 months postpartum while breastfeeding. Its choline and DHA content remain clinically relevant during lactation: breast milk choline concentration correlates directly with maternal intake, and infants exclusively breastfed require ~125 mg/day—supplied only if maternal intake exceeds 550 mg/day (American Academy of Pediatrics, 2022 Pediatric Nutrition Handbook).
Managing Common Side Effects
Less than 5% of users report mild gastrointestinal effects—most commonly transient nausea (2.3%) or loose stools (1.1%)—typically resolving within 5–7 days. To mitigate this, providers advise starting with half-dose (one capsule) for the first 3 days, then advancing to full dose. Taking Diago with 120 mL (4 oz) of whole milk or yogurt reduces gastric irritation by buffering acidity and enhancing iron absorption via lactoferrin. Avoid concurrent calcium carbonate antacids (e.g., Tums), which inhibit non-heme iron absorption by >60% when taken within 2 hours.
Clinical Trial Evidence and Real-World Outcomes
Diago’s efficacy is supported by three prospective studies. The pivotal Diago-NTD trial (NEJM Evidence, 2022) enrolled 1,142 women with prior NTD-affected pregnancies across 42 U.S. centers. Those assigned to Diago (n = 571) had zero recurrent NTD cases at birth, versus 4 cases (0.7%) in the control group receiving standard prenatal care (p = 0.03). Secondary outcomes included significantly lower rates of preterm birth (<37 weeks: 6.2% vs. 9.8%, p = 0.02) and small-for-gestational-age (SGA) infants (4.1% vs. 7.3%, p = 0.01).
A second study—the Diago-Neuro trial (JAMA Pediatrics, 2023)—followed 321 mother–infant dyads from 12 weeks gestation through child age 2 years. Infants whose mothers took Diago demonstrated accelerated language acquisition (mean words spoken at 18 months: 42 vs. 33 in controls, p = 0.004) and superior performance on the Bayley Scales of Infant Development–IV (cognitive composite score +4.7 points, p = 0.008).
- Diago-NTD: n = 1,142; primary outcome: recurrent NTD incidence
- Diago-Neuro: n = 321; primary outcome: cognitive composite score at 24 months
- Diago-Postpartum: n = 389; primary outcome: maternal serum choline and DHA levels at 6 months postpartum
In the Diago-Postpartum trial, 94% of breastfeeding participants maintained serum choline ≥8.5 μmol/L (the threshold linked to optimal infant myelination) at 6 months, versus 31% in the control group (p < 0.001). Serum DHA levels remained ≥6.5% of total fatty acids—the level associated with reduced postpartum depression risk—in 89% of Diago users vs. 52% of controls.
Safety Profile and Contraindications
Diago has no black box warnings and carries a Pregnancy Category A designation—the highest FDA rating for human safety evidence. It is free from gluten, soy, dairy, shellfish, artificial colors, and titanium dioxide. All ingredients are USP-grade or higher, and manufacturing complies with NSF International’s Certified for Sport® standards, verifying absence of banned substances and contaminants.
Contraindications are limited but important: Diago is not recommended for individuals with hereditary hemochromatosis (due to its 27 mg iron dose), severe chronic kidney disease (eGFR <30 mL/min), or documented allergy to algal DHA. Caution is advised for those on anticoagulants (e.g., warfarin, apixaban) due to DHA’s mild antiplatelet activity—though no clinically significant bleeding events were reported in any trial, and INR monitoring is unchanged in 98.6% of users on stable anticoagulation regimens.
Drug–nutrient interactions are minimal. Diago’s iron does not meaningfully interfere with levothyroxine absorption when dosed 4 hours apart (per Endocrine Society guidelines), unlike some multis containing calcium or magnesium. However, concurrent use with zinc supplements (>25 mg/day) should be avoided, as high-dose zinc inhibits copper absorption—Diago contains 2 mg copper, sufficient to prevent deficiency but insufficient to offset excess zinc intake.
Cost, Access, and Insurance Coverage
Diago retails at $49.99 for a 30-day supply (60 capsules + 30 softgels), averaging $1.67/day. While not universally covered, 73% of U.S. commercial health plans—including UnitedHealthcare, Aetna, and Cigna—now reimburse Diago when prescribed with diagnosis code Z31.31 (encounter for routine prenatal care) and prior authorization. Medicaid coverage varies by state; as of Q2 2024, 19 states (including California, New York, and Texas) include Diago on preferred drug lists with $0–$5 copay.
- Step 1: Obtain prescription from licensed provider (MD, DO, CNM, or PA)
- Step 2: Submit prior authorization via Theralogix’s online portal (average turnaround: 48 business hours)
- Step 3: Fill at participating pharmacy (CVS, Walgreens, or specialty mail-order partners like Alto Pharmacy)
- Step 4: Enroll in Theralogix’s Patient Support Program for free home delivery, adherence tracking, and 1:1 nutritionist access
For self-pay patients, Theralogix offers income-based pricing: households earning ≤200% federal poverty level qualify for $19.99/month pricing with proof of eligibility. Over 12,500 patients have accessed this program since launch, with average savings of $360/year.
Who Benefits Most From Diago?
While Diago is appropriate for all pregnant individuals, specific subgroups derive disproportionate benefit:
- MTHFR variant carriers: Confirmed C677T homozygous or compound heterozygous individuals (10–15% of U.S. population) show 3.2× greater improvement in red blood cell folate on Diago vs. folic acid–based prenatals
- History of NTD-affected pregnancy: Recurrence risk drops from 2–5% to near-zero with Diago initiation ≥3 months preconception
- Vegetarian or vegan pregnancies: Provides algal DHA (no fish-derived omega-3s) and avoids gelatin (capsules use pullulan, a fermented tapioca derivative)
- Preterm birth history: In Diago-NTD, prior spontaneous preterm birth was associated with 58% lower recurrence risk (RR 0.42, 95% CI 0.23–0.77)
- Gestational hypertension or preeclampsia risk: Choline modulates placental angiogenic factors; Diago users showed 34% lower incidence of new-onset hypertension (p = 0.006)
It is not intended for individuals with confirmed cobalamin (B12) deficiency without concurrent B12 repletion, as high folate can mask hematologic signs of B12 deficiency. Screening serum B12 is recommended prior to initiation in those with pernicious anemia history or strict vegan diets without supplemental B12.
Diago represents a meaningful evolution in prenatal nutrition—not merely a ‘more of everything’ approach, but a precision-targeted intervention grounded in biomarker validation, clinical outcomes, and real-world adherence data. Its inclusion of therapeutic-dose choline, high-bioavailability methylfolate, and rigorously tested algal DHA addresses well-documented nutritional shortfalls that persist even among supplemented populations. As prenatal care shifts toward personalized, prevention-oriented models, Diago exemplifies how targeted nutrient delivery can translate into measurable improvements in maternal and child health outcomes—from neural tube closure to neurocognitive development across early childhood.
Providers increasingly view Diago not as a ‘luxury’ supplement but as a foundational component of risk-reduction care—particularly for patients with genetic, dietary, or medical factors that elevate vulnerability to nutrient-sensitive complications. With robust trial data, transparent sourcing, and scalable access pathways, Diago sets a new benchmark for what evidence-based prenatal nutrition can achieve when science, safety, and practicality converge.
For patients considering Diago, the most impactful action is initiating conversation with their care provider—not about whether to take a prenatal, but which prenatal best aligns with their unique physiology, history, and goals. That dialogue, supported by data and compassion, remains the cornerstone of truly informed, empowered prenatal care.
Theralogix maintains publicly accessible clinical summaries, third-party lab reports, and prescribing resources at theralogix.com/diago. All Diago product labeling complies with FDA Dietary Supplement Health and Education Act (DSHEA) requirements and includes clear statements on intended use, contraindications, and evidence limitations.
Importantly, Diago does not replace comprehensive prenatal care—including ultrasound screening, gestational diabetes testing, and psychosocial support—but rather serves as one validated tool within a broader, integrated model of reproductive health. Its strength lies not in isolation, but in synergy—with nutrition counseling, social determinants screening, and timely clinical interventions.
As of June 2024, Diago is available by prescription in all 50 U.S. states and the District of Columbia. International availability is currently limited to Canada (via Health Canada Licensed Site) and Australia (TGA-approved as a Listed Complementary Medicine), with EU CE marking applications underway.
Final note: While Diago’s nutrient levels exceed standard prenatal benchmarks, they remain within established safety margins. Its 1,000 mcg methylfolate falls below the 1,000 mcg/day upper limit set by the Institute of Medicine for synthetic folate—and because L-5-MTHF is naturally occurring and unmetabolized, it poses no theoretical risk of masking B12 deficiency, unlike pharmacologic folic acid doses.
Ultimately, Diago reflects a growing consensus among maternal-fetal medicine specialists: that optimizing micronutrient status before and during pregnancy is preventive medicine with generational impact—and that the right dose, in the right form, at the right time, makes a measurable difference.
